Search

everythinglearnresearchcommunity

for

Search:↓

User asks if mixing RU58841 solution with Serioxyl is okay for better scalp coverage and worries about reduced effects.

Post Finasteride Syndrome (PFS) is debated, with some users reporting severe side effects from finasteride, while others believe these effects are rare or psychosomatic. Treatments discussed include finasteride, minoxidil, and RU58841.

The user is considering minoxidil, clascoterone, and fluridil for hair loss, avoiding finasteride and RU58841. They are also contemplating a hair transplant and exploring the resilience of transplanted hair without finasteride.

Gut microbiome imbalances can cause scalp inflammation and affect hair follicles, potentially leading to hair loss. Treatments include finasteride, peptides like BPC-157, TB-500, KPV, and lifestyle changes such as diet and exercise.

Breezula, a topical treatment, is anticipated to be available in the US by mid-2027 as a potential alternative to finasteride with fewer systemic side effects. There is ongoing debate about its effectiveness and some users report similar side effects to finasteride.

A 29-year-old shared their hair recovery progress using a liposomal topical finasteride/minoxidil solution, LLLT helmet, and vitamins, noting that transplants were only on the hairline. They highlighted the effectiveness of their regimen and addressed skepticism with photos.

Hair loss treatments like finasteride, minoxidil, and RU58841 are becoming more known, but many remain unaware of their effectiveness. There is hope for future advancements despite skepticism and misconceptions about current treatments.

The conversation is about hair regrowth using high-dose dutasteride, oral minoxidil, and microneedling. Users discuss seeing tiny hairs and hope they will become terminal, with advice to use derma rolling weekly for better results.

A user discusses their habit of analyzing others' hair due to their own hair thinning at 18. Another user mentions starting finasteride in 2010 and still having a full head of hair.

PG solvent is considered superior to K&B solvent for RU58841 and Pyralutamide due to cost and effectiveness. The user questions why they should use K&B when PG offers more benefits.

Exploring treatment options for male pattern baldness, including minoxidil, finasteride, and RU58841, with a focus on Eucapil, a topical agent. The post also discusses research from various sources about the efficacy of these treatments.

The conversation discusses using peptides BPC-157 and TB-500, combined with microneedling, to potentially enhance hair regrowth. The user plans to try BPC-157 due to its lower cost and reports of hair growth, despite limited human trials and concerns about side effects from other treatments like minoxidil and finasteride.

A young male in his twenties discusses hair loss, mentioning the use of Minoxidil, topical finasteride, and occasional derma rolling. He inquires about scalp inflammation, fibrosis, and the potential benefits of magnesium oil and scalp massages for improving blood flow and hair health.

Hair loss discussion mentions Minoxidil, finasteride, and RU58841 treatments. Regenepure shampoo's ketoconazole ingredient causes confusion due to inconsistent listings.

The user is treating hair loss with a regimen including Dutasteride, oral and topical Minoxidil, microneedling, and various supplements for overall health. They are considering adding tretinoin, stemoxydine/RU, DIM, Boron, and Fadogia Agretis to their routine.

PP405 is progressing to Phase 2b trials, with results expected in late 2025 or early 2026, and potential Phase 3 trials in 2026. Some users experienced side effects from finasteride and are hopeful for PP405 as an alternative treatment.

The conversation discusses the slow transition from baby hair to normal hair while using finasteride and transitioning to dutasteride, with progress except for the crown area. It's mentioned that hair thickening can take years, with each growth cycle potentially making the hair thicker, and this process can span over 6 months or more.

The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.

Finasteride can cause dry eyes and vision issues due to its impact on the meibomian glands. Users have mixed experiences, with some experiencing eye discomfort and others having no side effects.

The user experienced hair regrowth and thickening using 1mg oral finasteride, 3mg oral minoxidil, biotin, vitamin D, red light therapy, and microneedling. Some shedding occurred around 4-6 weeks into the treatment.

Hair loss discussion includes alfatradiol (Pantostin/Ell Cranell) as a potential treatment. Users share opinions on its effectiveness in their regimen.

New hair loss treatments like VDPHL01, PP405, Gt20029, and Breezula are anticipated, with VDPHL01 possibly releasing in 2027/28. Current treatments include finasteride, dutasteride, and minoxidil, but new options are eagerly awaited.

A 19-year-old with NW2-2.5 hair loss is starting finasteride soon, considering low dosages of 0.25mg daily or 0.5mg 3-5 times a week. They are also using derma stamping, ketoconazole shampoo, ACV washes, and various oils to maintain hair quality and reduce scalp itch.

The conversation discusses using topical finasteride and minoxidil for hair loss, focusing on the crown and mid-scalp areas. The user is optimistic about seeing results in 3 to 6 months.

PP405 is not commercially available or legitimate in Europe. Users are discussing the lack of availability of this product.

A user received KX-826 instead of RU58841 and is confused about their order. They are asking if others have experienced similar issues.

Hair loss treatments discussed: GT 20029, Pyrilutamide, Minoxidil, Finasteride, and Dutasteride. Some believe Dutasteride will replace Finasteride.

Epibiotech will offer off-the-shelf allogeneic hair multiplication treatment in South Korea, using dermal papilla cells from donors to grow hair in balding areas. This method is cheaper and less invasive than traditional hair transplants.

AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.